Ambitious problems demand collaborators who’ve earned the room

Our mission is to close the gap between when cancer can be caught and when it’s actually caught. That’s a bigger problem than any one lab, dataset, or model can solve alone — which is why every serious step we’ve taken has been taken alongside the people closest to the science.

Driving discovery together

Our culture of collaboration extends beyond the walls of our offices and underpins every one of our relationships — whether you’re an independent scientist, a research lab, an academic or clinical institution, or another pioneering partner working on the same problem from a different angle.

Together we are turning causal understanding of cancer biology into evidence that holds up outside a lab. With AI, longitudinal data and deep oncology domain expertise, we are working toward a new standard for early detection and therapy development — one built to reach the people who need it, not just the people near a tertiary centre.

And not a moment too soon.

Our partners

EIOMS

Health Voitho engages the Esperer Institute of Oncology & Metabolic Sciences (EIOMS) as its knowledge partner. EIOMS, the integrated knowledge partner of the Esperer Group, is a multidisciplinary translational research institute advancing the science of cancer, metabolism, and chronic disease prevention. Recognizing that metabolic dysregulation underlies both cancer progression and a broad spectrum of non-communicable diseases, EIOMS brings together molecular biology, clinical medicine, nutrition, immunology, microbiome science, implementation science, and digital health into a unified framework of metabolic resilience.

This partnership grounds Health Voitho's work in rigorous, translational science. As a platform for research, education, innovation, and policy translation, EIOMS bridges scientific discovery and real-world health impact, building the next generation of clinicians, researchers, and public health leaders equipped to turn precision prevention into better patient outcomes and healthier communities.

Our partnership principles

Rigor

A target or biomarker doesn’t earn a partner’s trust because it looks promising — it earns it because it holds up against causal, real-world evidence. We validate before we hand anything downstream, not after.

Reciprocity

A partner’s domain knowledge and data go into every model we build together; our causal modelling and closed-loop validation come back out. It’s an exchange, not a service performed on a partner’s behalf.

Velocity

Cancer caught early is a different disease than cancer caught late. Every partnership is judged against that clock, not against a publication or funding timeline.

Reach

Validated in a partnership isn’t the same as reaching a patient outside a tertiary centre. Our partnerships exist to close that specific gap — one pathway at a time.

If you’re a scientist, a lab, or an institution working on the same problem — we’d like to hear from you.

Partner with us